Physician profile
Sarah Mun
NPI 1023467818
$2,066.60
in general payments reported to CMS, 2019-2025
24 companies · $887 in 2025
The $887 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $14.38 · 2024: $1,166 · 2025: $887.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,052.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,052.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $305.07 | 2021-2025 | |
| Amgen INC. | $224.43 | 2024-2025 | Repatha, Evenity, Repatha |
| Astellas Pharma US INC | $200.93 | 2024-2025 | Veozah |
| Novo Nordisk INC | $193.64 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $181.09 | 2024-2025 | |
| Lilly USA, LLC | $168.95 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Dexcom, INC. | $135.49 | 2024-2025 | Dexcom G6 Transmitter |
| Saluda Medical Americas, INC. | $94.06 | 2024 | Evoke |
| Exact Sciences Corporation | $88.99 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Inspire Medical Systems, INC. | $79.95 | 2024-2025 | Inspire |
| Astrazeneca Pharmaceuticals LP | $65.14 | 2024-2025 | Airsupra |
| Shield Therapeutics INC | $52.38 | 2025 | |
| Actelion Pharmaceuticals US, INC. | $37.00 | 2024 | Opsumit, Uptravi |
| Abbott Laboratories | $36.05 | 2025 | Freestyle Libre 3 |
| Teleflex LLC | $23.48 | 2024 | Urolift |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $22.11 | 2025 | |
| Corium, LLC | $21.78 | 2025 | Azstarys |
| Medtronic, INC. | $21.31 | 2024 | Interstim |
| Alexion Pharmaceuticals, INC. | $21.10 | 2024 | Strensiq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.96 | 2025 | Xifaxan |
| Glaxosmithkline, LLC. | $19.05 | 2024 | Arexvy, Shingrix |
| Optinose US, INC. | $18.67 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.92 | 2025 | |
| Esperion Therapeutics, INC. | $17.05 | 2025 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Mun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.